Mga Batayang Estadistika
| CIK | 1815776 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Graphite Bio, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
Exhibit 99.1 LENZ Therapeutics Announces US FDA Approval of VIZZTM for the Treatment of Presbyopia VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and pr |
|
| July 31, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F |
|
| July 30, 2025 |
Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercializati |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2025 |
Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash ru |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 15, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission |
|
| April 14, 2025 |
Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-286398 PROSPECTUS SUPPLEMENT To prospectus dated April 14, 2025 Up to $150,000,000 Common Stock We have entered into a sales agreement (the “sales agreement”) with TD Securities (USA) LLC (“TD Cowen”), dated April 4, 2025, relating to shares of our common stock, par value $0.00001 per share (“common stock”), offered by this prospectus supplemen |
|
| April 14, 2025 |
13,070,093 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-286397 13,070,093 Shares of Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of (i) 12,922,451 shares of common stock, par value $0.00001 per share (the “Common Stock”) held by the se |
|
| April 10, 2025 |
April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: LENZ Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-286397 Acceleration Request Requested Date: April 14, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gent |
|
| April 10, 2025 |
April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: LENZ Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-286398 Acceleration Request Requested Date: April 14, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gent |
|
| April 9, 2025 |
1,022,809 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278393 PROSPECTUS 1,022,809 Shares of Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 1,022,809 shares of common stock, par value $0.00001 per share (the “Common Stock”) issued in a private |
|
| April 9, 2025 |
1,578,947 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282036 PROSPECTUS 1,578,947 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus (the “selling stockholder”) of 1,578,947 shares of common stock, par value $0.00001 per share (the “Common Stock”) that were sold and issued to the selling stockholder in a private placement pursuant to a |
|
| April 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LENZ Therapeutics, Inc. |
|
| April 4, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) LENZ Therapeutics, Inc. |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| April 4, 2025 |
Exhibit 1.1 LENZ THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT April 4, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| April 4, 2025 |
, 2025, by and between the Registrant and TD Securities (USA) LLC Exhibit 1.2 LENZ THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT April 4, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that |
|
| April 4, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F |
|
| April 4, 2025 |
Exhibit 4.3 LENZ THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| March 19, 2025 |
Exhibit 19.1 LENZ THERAPEUTICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY (Adopted on March 21, 2024; Amended and Restated on November 12, 2024) A.POLICY OVERVIEW LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securi |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2025 |
Exhibit 97.1 LENZ THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted on March 21, 2024; Effective upon the closing of the merger contemplated by the Registration Statement on Form S-4 (File No. 333-275919) LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the |
|
| March 19, 2025 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the capital stock of LENZ Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) is a summary of certain provisions of the securities that are registered under Section 12 of the Securities and Exchange Act of 1934, as amended, and does not |
|
| March 19, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LENZ Therapeutics, Inc. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405 |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
Exhibit 99.1 LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025 Cash, ca |
|
| November 14, 2024 |
LENZ / LENZ Therapeutics, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 lenz1015247sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lenz Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Che |
|
| November 8, 2024 |
LENZ / LENZ Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d871919dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commissio |
|
| November 6, 2024 |
Exhibit 99.1 LENZ Therapeutics Reports Third Quarter 2024 Financial Results New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash, cash equivalents and |
|
| November 6, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| November 6, 2024 |
1,578,947 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated September 19, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 28, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| October 28, 2024 |
Exhibit 99.1 CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically signif |
|
| October 28, 2024 |
1,578,947 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated September 19, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| October 28, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commissio |
|
| September 19, 2024 |
1,578,947 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-282036 PROSPECTUS 1,578,947 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus (the “selling stockholder”) of 1,578,947 shares of common stock, par value $0.00001 per share (the “Common Stock”) that were sold and issued to the selling stockholder in a private placement purs |
|
| September 17, 2024 |
September 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tim Buchmiller Re: LENZ Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-282036 Acceleration Request Requested Date: September 19, 2024 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and |
|
| September 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) LENZ Therapeutics, Inc. |
|
| September 11, 2024 |
As filed with the Securities and Exchange Commission on September 11, 2024 As filed with the Securities and Exchange Commission on September 11, 2024 Registration No. |
|
| August 14, 2024 |
Stock Purchase Agreement by and between LENZ Therapeutics, Inc. and Ridgeback Capital Investment Exhibit 10.1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of July 14, 2024 (the “Effective Date”), by and among LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), and Ridgeback Capital Investments L.P. (the “Purchaser”). WHEREAS, the Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, an aggregate |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| August 14, 2024 |
Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2024 Financial Results Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened financial position with $30 million private placement from Ridgeback Capital in July 2024 Pro forma cash, c |
|
| August 12, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| August 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
Exhibit 99.1 LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia SAN DIEGO, CA – August 12, 2024 – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in pe |
|
| July 29, 2024 |
EX-99.1 2 tm2420256d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that statements on Schedules 13G and/or 13D and Forms 3, 4 and 5 with respect to the securities of LENZ Therapeutics, Inc. and any amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of R |
|
| July 29, 2024 |
LENZ / LENZ Therapeutics, Inc. / Ridgeback Capital Investments L.P. - SC 13G Passive Investment SC 13G 1 tm2420256d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. ) UNDER THE SECURITIES EXCHANGE ACT OF 19341 LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) July 17, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| July 15, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| July 15, 2024 |
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital Exhibit 99.1 LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital SAN DIEGO, CA – July 15, 2024 – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it has entered into a stock purchase |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F |
|
| May 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LENZ Therapeutics, Inc. |
|
| May 21, 2024 |
As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No. |
|
| May 9, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| May 8, 2024 |
Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3 CLARITY study to be presented at Key Opinion Leader event planned for June 18, 2024 Completed merger w |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 11, 2024 |
1,297,411 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-278393 1,297,411 Shares of Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 1,297,411 shares of common stock, par value $0.00001 per share (the “Common Stock”) issued in |
|
| April 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) LENZ Therapeutics, Inc. |
|
| April 9, 2024 |
As filed with the Securities and Exchange Commission on April 8, 2024 As filed with the Securities and Exchange Commission on April 8, 2024 Registration No. |
|
| April 8, 2024 |
April 8, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Chris Edwards Re: LENZ Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278393 Acceleration Request Requested Date: April 10, 2024 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen |
|
| April 8, 2024 |
SC 13G/A 1 grph13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Lenz Therapeutics, Inc. (f/k/a Graphite Bio, Inc.) (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Sta |
|
| April 3, 2024 |
NASDAQ: LENZ Topline CLARITY Results Phase 3 Clinical Trials April 3rd 2024 This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. |
|
| April 3, 2024 |
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials –LNZ100 selected as lead candidate –Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours –Rapid onset and long duration shown with 71% of participants achieving three-lines or greater improvement at 30 minutes and 40% at 10 hours –New Drug Application submission anticipated in mid-2024 –Company to host a conference call and webcast today at 8:00 a. |
|
| April 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F |
|
| March 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) LENZ Therapeutics, Inc. |
|
| March 29, 2024 |
Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Incorporation LENZ Therapeutics Operations, Inc. Delaware |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 28, 2024 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be |
|
| March 28, 2024 |
Alpha Wave Ventures GP, Ltd - LENZ THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENZ Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| March 28, 2024 |
RA CAPITAL MANAGEMENT, L.P. - SC 13D SC 13D 1 tm2410120d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LENZ Therapeutics, Inc. (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 52635N103 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floo |
|
| March 25, 2024 |
EX-99.11 2 d810139dex9911.htm EX-99.11 Exhibit 11 Joint Filing Agreement The undersigned hereby agree that the attached Amendment No. 2 to Schedule 13D (or any amendment thereto) relating to the Common Stock of LENZ Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Amendment No. 2 to Schedule 13D. March 25, 2024 Vers |
|
| March 25, 2024 |
SC 13G 1 p24-1293sc13g.htm LENZ THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| March 25, 2024 |
GRPH / Graphite Bio, Inc. / Samsara BioCapital, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm249756d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Statement) Ch |
|
| March 25, 2024 |
GRPH / Graphite Bio, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) Vers |
|
| March 22, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GRAPHITE BIO, INC. Graphite Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Graphite Bio, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Dela |
|
| March 22, 2024 |
Exhibit 10.12 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter March 21, 2024 Marc Odrich Via email Dear Marc: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is to |
|
| March 22, 2024 |
Exhibit 10.10 LENZ THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under Code |
|
| March 22, 2024 |
Exhibit 10.13 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter March 21, 2024 Shawn Olsson Via email Dear Shawn: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is |
|
| March 22, 2024 |
Exhibit 10.21 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of March 21, 2024, by and among Graphite Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several investors signatory hereto (each, an “Investor” and collectively, the “Investors”). RECITALS WHEREAS, the Company is party to that |
|
| March 22, 2024 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Merger On November 14, 2023, Graphite Bio, Inc., a Delaware corporation (“Graphite”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and between Graphite, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Graphite (“Merger Sub”), and Lenz Therapeutics, Inc., a Delawa |
|
| March 22, 2024 |
Exhibit 10.9 LENZ THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s business. (b) Awar |
|
| March 22, 2024 |
Exhibit 10.6 GRAPHITE BIO, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November 14, 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHEREAS, Parent, Generate Merger |
|
| March 22, 2024 |
Exhibit 10.8 LOCK-UP AGREEMENT November 14, 2023 Graphite Bio, Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Graphite Bio, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of November 14, 2023 (as the same may be amende |
|
| March 22, 2024 |
Report of Independent Registered Public Accounting Firm Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Lenz Therapeutics, Inc. |
|
| March 22, 2024 |
Exhibit 10.11 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter March 21, 2024 Evert Schimmelpennink Via email Dear Evert: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agre |
|
| March 22, 2024 |
Exhibit 10.7 LENZ THERAPEUTICS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November 14, 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Parent, Gener |
|
| March 22, 2024 |
Exhibit 10.16 LENZ THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Co |
|
| March 22, 2024 |
Exhibit 16.1 March 21, 2024 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-7561 Ladies and Gentlemen: We have read LENZ Therapeutics, Inc. statements (formally known as Graphite Bio, Inc.) included under Item 4.01 of its Form 8-K dated March 21, 2024 and have the following comments: 1.We are in agreement with the statements made in part (a) Dismissal of Independent Regi |
|
| March 22, 2024 |
Exhibit 99.3 LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress – LENZ Therapeutics to debut on Nasdaq under the ticker symbol “LENZ” as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 |
|
| March 22, 2024 |
Exhibit 10.14 LENZ Therapeutics, Inc. Employment Letter March 21, 2024 Dan Chevallard Via email Dear Dan: LENZ Therapeutics, Inc. (the “Company” or “we”) is pleased to offer you employment pursuant to this letter agreement (the “Agreement”), effective as of March 21, 2024 (the “Effective Date”). 1.Position. Commencing on the Effective Date, you will be employed as the Chief Financial Officer of th |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 83-4867570 (State or other jurisdiction of incorporation) (Commission File |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 83-4867570 (State or other jurisdiction of incorporation) (Commission File |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| March 8, 2024 |
Exhibit 99.1 Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger SOUTH SAN FRANCISCO, CA – March 8, 2024 – Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special divid |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| March 5, 2024 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 27, 2024 |
Exhibit 10.27 GRAPHITE BIO, INC. COMPENSATION RECOVERY POLICY Adopted as of November 14, 2023 Graphite Bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defi |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| February 27, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. None. |
|
| February 13, 2024 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-275919 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Graphite Bio, Inc. and Lenz Therapeutics, Inc., Graphite Bio, Inc., a Delaware corporation (“Graphite”), and Lenz Therapeutics, Inc., a Delaware corporation (“LENZ”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) on November 14, 2 |
|
| February 9, 2024 |
Graphite Bio, Inc. 611 Gateway Blvd, Suite 120 South San Francisco, CA 94080 Graphite Bio, Inc. 611 Gateway Blvd, Suite 120 South San Francisco, CA 94080 February 9, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attention: Ms. Doris Stacey Gama Mr. Jason Drory Mr. Eric Atallah Ms. Lynn Dicker Re: Graphite Bio, Inc. Acceleration Request for Registration Statement on F |
|
| February 9, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on February 9 , 2024 No. |
|
| February 9, 2024 |
Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR February 9, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| February 5, 2024 |
Asset Purchase Agreement, by and between Maro Bio Inc. and Graphite Bio, Inc., dated August 1, 2023. Exhibit 10.45 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Execution Version ASSET PURCHASE AGREEMENT by and between MARO BIO INC., a Delaware corporation and GRAPHITE BIO, INC., a Dela |
|
| February 5, 2024 |
Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR February 5, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| February 5, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of Graphite Bio, Inc. and further agree to the filing of thi |
|
| February 5, 2024 |
GRPH / Graphite Bio, Inc. / Porteus Matthew - SC 13G/A Passive Investment SC 13G/A 1 d710000dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GRAPHITE BIO, INC. (Name of Issuer) Common Stock, Par Value $0.00001 Per Share (Title of Class of Securities) 38870X104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 5, 2024 |
EXHIBIT 10.46 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AND OPTION AGREEMENT This License and Option Agreement (this “Agreement”) is entered into as of August 4, 2023 (the “E |
|
| February 5, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on February 5, 2024 No. |
|
| February 5, 2024 |
GRPH / Graphite Bio, Inc. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 18, 2024 |
List of Subsidiaries of Graphite Bio, Inc. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. Legal Name State of Organization Generate Merger Sub, Inc. Delaware |
|
| January 18, 2024 |
Exhibit 10.30 [***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of April 12th, 2022 (the “Effective Date”) by an |
|
| January 18, 2024 |
Table of Contents As filed with the Securities and Exchange Commission o n Jan uary 17 , 2024 No. |
|
| January 18, 2024 |
Exhibit 10.44 LENZ THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.), a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Ind |
|
| January 18, 2024 |
Exhibit 99.2 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| January 17, 2024 |
Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR January 17, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 26, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 6, 2023 |
Exhibit 99.5 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| December 6, 2023 |
Amended and Restated By-Laws of LENZ Therapeutics, Inc., as currently in effect. Exhibit 4.4 Amended and Restated BY-LAWS OF Lenz Therapeutics, Inc. (a Delaware corporation) Adopted by the Sole Incorporator on October 28, 2020 Affirmed by the Board of Directors on October 30, 2020 Amended and restated on March 1, 2023 Amended and Restated BY-LAWS OF Lenz Therapeutics, Inc. ARTICLE 1.- Stockholders 1.1 Place of Meetings. All meetings of stockholders shall be held at such place |
|
| December 6, 2023 |
Exhibit 4.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LENZ THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) LENZ THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That th |
|
| December 6, 2023 |
Exhibit 10.41 LENZ THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY This Executive Change in Control and Severance Policy (the “Policy”) is designed to provide certain protections to a select group of key employees of LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (“Lenz” or the “Company”) or any of its subsidiaries if their employment is involuntarily terminated |
|
| December 6, 2023 |
Exhibit 99.3 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| December 6, 2023 |
Exhibit 10.38 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter , 2024 Evert Schimmelpennink Via email Dear Evert: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is |
|
| December 6, 2023 |
Exhibit 99.7 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| December 6, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on December 6, 2023 No. |
|
| December 6, 2023 |
Exhibit 10.29 AIR STANDARD MULTI-TENANT OFFICE LEASE - GROSS 1. Basic Provisions (“Basic Provisions”). 1.1 Parties. This Lease (“Lease”), dated for reference purposes only February 4, 2022 ,1s made by and between Hankey Investment Company, L.P., a California limited partnership (“Lessor”)and Lenz Therapeutics, Inc., a Delaware corporation (“Lessee”), (collectively the “Parties”, or Individually a |
|
| December 6, 2023 |
Exhibit 10.31 PRESBYOPIA THERAPIES, INC. 2020 EQUITY INCENTIVE PLAN Adopted by the Board of Directors on October 30, 2020 Approved by the Stockholders on November 3, 2020 1. Purposes of the Plan. The purposes of this 2020 Equity Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consult |
|
| December 6, 2023 |
Outside Director Compensation Policy, to be in effect upon completion of the merger. Exhibit 10.42 LENZ THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Co |
|
| December 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) GRAPHITE BIO, INC. |
|
| December 6, 2023 |
Exhibit 4.5 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI |
|
| December 6, 2023 |
Exhibit 10.43 LENZ THERAPEUTICS, INC. EMPLOYEE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payable t |
|
| December 6, 2023 |
Consent of Leerink Partners LLC. Exhibit 99.8 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated November 14, 2023, to the Board of Directors of Graphite Bio, Inc., included as Annex B to the proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Graphite Bio, Inc., to be filed on the date hereof, and to the references to such opinion in such proxy statemen |
|
| December 6, 2023 |
Warrant to Purchase Shares of LENZ Common Stock, dated December 19, 2020. Exhibit 4.6 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (THIS “WARRANT”) AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE OFFERED, SOLD, |
|
| December 6, 2023 |
Exhibit 99.4 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| December 6, 2023 |
List of Subsidiaries of Graphite Bio, Inc. Exhibit 21.2 SUBSIDIARIES OF GRAPHITE BIO, INC. None. |
|
| December 6, 2023 |
Exhibit 10.39 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter , 2024 Shawn Olsson Via email Dear Shawn: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is to confi |
|
| December 6, 2023 |
Exhibit 10.40 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter , 2024 Marc Odrich Via email Dear Marc: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is to confirm |
|
| December 6, 2023 |
Exhibit 99.6 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| November 17, 2023 |
GRPH / Graphite Bio Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d598930dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 3887 |
|
| November 15, 2023 |
Exhibit 10.3 LOCK-UP AGREEMENT , 2023 Graphite Bio, Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Graphite Bio, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of November [•], 2023 (as the same may be amended from tim |
|
| November 15, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among GRAPHITE BIO, INC., GENERATE MERGER SUB, INC. and LENZ THERAPEUTICS, INC. Dated as of November 14, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 3 Section 1.1 Certain Definitions 3 Section 1.2 Interpretation 9 Section 1.3 Currency 9 ARTICLE II THE MERGER 10 Section 2.1 Formation of Merger Sub 10 Section 2.2 The Merger 10 S |
|
| November 15, 2023 |
Filed by Graphite Bio, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Graphite Bio, Inc. Commission File No.: 001-40532 Date: November 15, 2023 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of November 14, 202 |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 15, 2023 |
Exhibit 99.2 + Merger Announcement November 2023 Legends Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed merger by and between Graphi |
|
| November 15, 2023 |
Exhibit 10.4 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of November 14, 2023 (the “Effective Date”), by and among Graphite Bio, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”). WHEREAS, the Company is party to that certain Agreeme |
|
| November 15, 2023 |
Exhibit 99.1 LENZ Therapeutics and Graphite Bio Announce Merger Agreement - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Co |
|
| November 15, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 15, 2023 |
Exhibit 10.1 GRAPHITE BIO, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November [•], 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHEREAS, Parent, Generate Merge |
|
| November 15, 2023 |
Form of LENZ Support Agreement Exhibit 10.2 LENZ THERAPEUTICS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November [•], 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Parent, Gene |
|
| November 13, 2023 |
Exhibit 10.1 August 18, 2023 Kim Drapkin Via Electronic Delivery Dear Kim: It is my great pleasure to present this offer letter to you to join Graphite Bio, Inc. (the “Company”) as our Chief Executive Officer. The entire board of directors of the Company (the “Board”) and I are very excited to have you as a member of the Graphite Bio team. Your experiences and accomplishments are consistent with t |
|
| November 13, 2023 |
Exhibit 10.2 GRAPHITE BIO, INC. September 5, 2023 PERSONAL AND CONFIDENTIAL Josh Lehrer Re: Separation Agreement and Release Dear Josh: This letter confirms our previous discussions concerning your employment with Graphite Bio, Inc. (the “Company”). On August 21, 2023 (the “Termination Date”), your employment with the Company shall end and your status with the Company shall change to no longer emp |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| October 30, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this "Amendment") is entered into as of the 26th day of October, 2023 (the “Amendment Effective Date”), by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company (" XE "Landlord" Landlord"), and GRAPHITE BIO, INC., a Delaware corporation (" XE "Tenant" Tenant"). r e c i t a l s : A. Landlord and Tenant en |
|
| October 30, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| October 30, 2023 |
Sublease agreement by and between Graphite Bio, Inc. and Soleil Labs, LLC, dated October 26, 2023 Exhibit 10.1 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of October 26, 2023, and is made by and between Graphite Bio, Inc., a Delaware corporation (“Sublessor”), and Soleil Labs, LLC, a Delaware limited liability company (“Sublessee”). Sublessor and Sublessee hereby agree as follows: 1. Recitals: This Sublease is made with reference to the fact that BAYSIDE AREA DE |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporati |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 23, 2023 |
Graphite Bio Announces Departure of Chief Financial Officer Exhibit 99.1 Graphite Bio Announces Departure of Chief Financial Officer SOUTH SAN FRANCISCO, Calif., June 23, 2023 – Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensu |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. |
|
| March 20, 2023 |
Exhibit 10.24 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. MASTER DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (for cell therapy services) This Master Developm |
|
| March 20, 2023 |
Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results SOUTH SAN FRANCISCO, Calif., March 20, 2023 – Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. “As announced last month, Graphite Bio has initiated a process to evaluate strategic alternatives that m |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 20, 2023 |
As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No. |
|
| March 20, 2023 |
EX-FILING FEES 4 grph-exfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Graphite Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amoun |
|
| March 20, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. None. |
|
| March 16, 2023 |
, 2023 [NAME] [ADDRESS] RE: Retention and Severance Agreement Dear [NAME]: The Compensation Committee (“Committee”) of the Board of Directors (the “Board”) of Graphite Bio, Inc. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 22, 2023 |
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring EX-99 2 grph-ex991.htm EX-99.1 Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring SOUTH SAN FRANCISCO, Calif., February 22, 2023 – Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of n |
|
| February 14, 2023 |
GRPH / Graphite Bio, Inc. / Samsara BioCapital, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236534d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 38870X104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec |
|
| January 9, 2023 |
GRPH / Graphite Bio, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 grph13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 38870X104 (CUSIP Number) January 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 5, 2023 |
Exhibit 99.1 Exhibit 99.1 Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., January 5, 2023 ? Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious advers |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 12, 2022 |
Exhibit 99.1 Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) SOUTH SAN FRANCISCO, Calif., December 11, 2022 – Graphite Bio, Inc. (Nasdaq: GRPH), |
|
| November 18, 2022 |
GRPH / Graphite Bio, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 38870X104 (CUSIP Number) November 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 9, 2022 |
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December Entered strategic partnership with Philadelphia-based WuXi Advanced Therapies for the manufacturing of nula-cel Bolstered company leadership with hiring of senior vice president of development $305. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| November 3, 2022 |
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition Exhibit 99.1 Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition SOUTH SAN FRANCISCO, Calif., November 3, 2022 ? Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced th |
|
| November 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| August 11, 2022 |
Exhibit 99.1 Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Initial proof-of-concept data from Phase 1/2 CEDAR trial anticipated in mid-2023 SOUTH SAN FRANCISCO, Calif., August 11, 2022 ? Graphite Bio |
|
| August 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 11, 2022 |
Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; initial proof-of-concept data now anticipated in mid-2023 Presented preclinical gene replacement data for GPH102 in beta-thalassemia at AS |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 26, 2022 |
Graphite Bio, Inc. 201 Haskins Way, Suite 210 South San Francisco, CA 94080 Graphite Bio, Inc. 201 Haskins Way, Suite 210 South San Francisco, CA 94080 July 26, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Graphite Bio, Inc.: Registration Statement on Form S-3 filed July 21, 2022 (File No. 333-266262) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities |
|
| July 21, 2022 |
Exhibit 1.2 GRAPHITE BIO, INC. Shares of Common Stock (par value $0.00001 per share) Controlled Equity OfferingSM Sales Agreement July 21, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Graphite Bio, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance and S |
|
| July 21, 2022 |
Exhibit 107.1 CALCULATION OF REGISTRATION FEE Form S-3 (Form Type) Graphite Bio, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration |
|
| July 21, 2022 |
Table of Contents Exhibit 4.5 GRAPHITE BIO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities Table of Contents TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of S |
|
| July 21, 2022 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.4 GRAPHITE BIO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Sect |
|
| July 21, 2022 |
As filed with the Securities and Exchange Commission on July 21, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 21, 2022 Registration No. |
|
| July 13, 2022 |
Exhibit 99.1 Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore SOUTH SAN FRANCISCO, Calif., May 16, 2022?Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing th |
|
| July 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 16, 2022 |
Exhibit 99.1 Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting Trial-in-progress poster of Phase 1/2 CEDAR trial evaluating GPH101 for sickle cell disease to be presented as an encore SOUTH SAN FRANCISCO, Calif., May 16, 2022 ? Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 12, 2022 |
Exhibit 99.1 Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results GPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical trial on track for second half of 2022, with initial proof-of-concept data anticipated in 2023 Oral presentation highlighting preclinical data for GPH102 for beta-thalassemia a |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| March 21, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. None. |
|
| March 21, 2022 |
As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No. |
|
| March 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Graphite Bio, Inc. |
|
| March 21, 2022 |
Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results Patient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for second half of 2022, with initial proof-of-concept data anticipated in 2023 Prioritized R&D to maximize capabilities of company?s |
|
| March 21, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the capital stock of Graphite Bio, Inc. (the ?Company,? ?we,? ?us,? and ?our?) is a summary of certain provisions of the securities that are registered under Section 12 of the Securities and Exchange Act of 1934, as amended, and does not purpo |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| March 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2022 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 21, 2022 |
Exhibit 10.23 October 20, 2021 Alethia Young Via Electronic Delivery Dear Alethia: It is my great pleasure to present this offer letter to you to join Graphite Bio, Inc. (the ?Company? or ?Graphite Bio?) as our Chief Financial Officer. The entire board of directors of the Company (the ?Board?) and I are very excited to have you as a member of the Graphite Bio team. Your experiences and accomplishm |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 2, 2022 |
Graphite Bio Appoints Alethia Young as Chief Financial Officer Exhibit 99.1 Graphite Bio Appoints Alethia Young as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., March 2, 2022 ? Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins G |
|
| February 14, 2022 |
GRPH / Graphite Bio, Inc. / Porteus Matthew - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GRAPHITE BIO, Inc. (Name of Issuer) Common Stock, Par Value $0.00001 Per Share (Title of Class of Securities) 38870X104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2022 |
GRPH / Graphite Bio, Inc. / Samsara BioCapital, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 38870X104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 20, 2021 |
Lease Agreement between the Registrant and Bayside Area Development, LLC dated December 16, 2021 Exhibit 10.1 NEXUS ON GRAND LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and GRAPHITE BIO, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION 1. D |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 17, 2021 |
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease GPH101 designed to directly correct the genetic mutation responsible for sickle cell disease First patient expected to be treated in first half of 2022, with initial proof-of-concept data anticipated by end of 2022 SOUTH SAN FRANCISCO, Calif. |
|
| November 16, 2021 |
Sublease Agreement between the Registrant and Annexon, Inc. dated November 10, 2021 Exhibit 10.1 SUBLEASE THIS SUBLEASE (this "Sublease") is dated for reference purposes as of November 5, 2021, and is made by and between Annexon, Inc., a Delaware corporation ("Sublandlord "), and Graphite Bio, Inc., a Delaware corporation (?Subtenant"). Sublandlord and Subtenant agree as follows: 1.Recitals: HCP LS Brisbane, LLC, a Delaware limited liability company, as Landlord ("Master Landlord |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 10, 2021 |
Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results Recruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites Details about CEDAR trial to be presented at 63rd ASH Annual Meeting and Exposition in December $395.0 million in cash, cash equivalents and restricted cash as of September 30, 2021 SOUTH SAN |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 GRAPHITE BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 12, 2021 |
Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results On track to enroll first patient in Phase 1/2 clinical trial of GPH101 for sickle cell disease in the second half of 2021 Expanded leadership team with hiring of CSO and three new appointments to board of directors Completed upsized initial public offering of common stock, raising $273.7 million in |
